Eton Pharmaceuticals reported total net revenues of $79.95M for the twelve months ended December 31, 2025, an increase from $39.01M in 2024, resulting in a gross profit of $42.74M.
Bullish
Eton Pharmaceuticals expanded its product portfolio with eight commercial rare disease products and five late-stage candidates, driving increased revenues and gross profit, supported by strong business development and regulatory expertise.
Bearish
Eton Pharmaceuticals faces revenue constraints from healthcare reforms and PBM practices, intense competition in rare disease markets, and significant risks from intellectual property litigation and protection challenges.